Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation

被引:60
作者
Paranjpe, PV
Chen, Y
Kholodovych, V
Welsh, W
Stein, S
Sinka, PJ
机构
[1] Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
关键词
camptothecin; prodrugs; targeted delivery; receptor-mediated endocytosis; PEG conjugates;
D O I
10.1016/j.jconrel.2004.08.030
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Camptothecin (CPT) presents numerous challenges associated with optimal transport and delivery including variability in clinically observed effects, low target tissue concentrations and severe and unpredictable toxicity. The objective of the present study was to optimize the delivery of CPT by targeting it to cancer cells using an endogenous receptor system. A novel CPT bioconjugate was synthesized using carbodiimide chemistry with a linear poly(ethylene glycol) (PEG) and amino acid glycine as the spacer and linker respectively. Folic acid was used as the targeting ligand to take advantage of folate receptor mediated endocytosis. The bioconjugate was extensively characterized using MALDI, proton NMR, FT-TR and amino acid analysis. Furthermore, the bioconjugate was evaluated in vitro for specific targeting to folate receptor-expressing KB cells, a human nasopharyngeal carcinoma. Finally, the delivery system was evaluated for cytotoxicity using a MTT based assay. The results indicate significantly higher efficacy of the bioconjugate in comparison to CPT. A control conjugate without PEG demonstrated no improvement in efficacy over untargeted CPT emphasizing the importance of spacer between the anticancer compounds and targeting moiety. This bioconjugate represents the 'first-in-series' of targeted bioconjugates and serves as prototype for improving tumor cell concentration and efficacy. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:275 / 292
页数:18
相关论文
共 51 条
[1]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[2]   Developments with targeted enzymes in cancer therapy [J].
Bagshawe, KD ;
Sharma, SK ;
Burke, PJ ;
Melton, RG ;
Knox, RJ .
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (05) :579-583
[3]   SYNTHESIS OF CLUSTER GALACTOSIDES WITH HIGH-AFFINITY FOR THE HEPATIC ASIALOGLYCOPROTEIN RECEPTOR [J].
BIESSEN, EAL ;
BEUTING, DM ;
ROELEN, HCPF ;
VANDEMAREL, GA ;
VANBOOM, JH ;
VANBERKEL, TJC .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (09) :1538-1546
[4]   THE STRUCTURAL BASIS OF CAMPTOTHECIN INTERACTIONS WITH HUMAN SERUM-ALBUMIN - IMPACT ON DRUG STABILITY [J].
BURKE, TG ;
MI, ZH .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (01) :40-46
[5]   Polymeric prodrug for release of an antitumoral agent by specific enzymes [J].
Cavallaro, G ;
Pitarresi, C ;
Licciardi, M ;
Giammona, G .
BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :143-151
[6]   Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates [J].
Cheng, JJ ;
Khin, KT ;
Jensen, GS ;
Liu, AJ ;
Davis, ME .
BIOCONJUGATE CHEMISTRY, 2003, 14 (05) :1007-1017
[7]   Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker [J].
Conover, CD ;
Greenwald, RB ;
Pendri, A ;
Gilbert, CW ;
Shum, KL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (05) :407-414
[8]   Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides [J].
Dharap, SS ;
Qiu, B ;
Williams, GC ;
Sinko, P ;
Stein, S ;
Minko, T .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) :61-73
[9]   Preparation and tumor cell uptake of poly(N-isopropylacrylamide) folate conjugates [J].
Dubé, D ;
Francis, M ;
Leroux, JC ;
Winnik, FM .
BIOCONJUGATE CHEMISTRY, 2002, 13 (03) :685-692
[10]   Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs [J].
Dubowchik, GM ;
Walker, MA .
PHARMACOLOGY & THERAPEUTICS, 1999, 83 (02) :67-123